Vivesto Stock

Vivesto Financial Leverage

The Financial Leverage (Equity Multiplier) of Vivesto (VIVE.ST) as of Aug 10, 2026 is 1.12. In the previous year, Financial Leverage (Equity Multiplier) was 1.09 — a change of 2.02% (higher).

Financial Leverage

1.12

YoY

2.02%

Last updated:

Financial Leverage (Equity Multiplier) of Vivesto is 2026 1.12 . Financial Leverage (Equity Multiplier) of Vivesto was 2025 1.09 . It decreases by 2.02% higher compared to the previous year.
Access this data via the Eulerpool API

Vivesto Stock analysis

What does Vivesto do? Oasmia Pharmaceutical AB is a Swedish pharmaceutical company that specializes in the development and marketing of innovative cancer and pain medications. The company was founded in 1998 and is headquartered in Uppsala, Sweden. Vivesto is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vivesto stock

Financial Leverage (Equity Multiplier) of Vivesto is 1.12 in 2026.

Financial Leverage (Equity Multiplier) of Vivesto changed from 1.09 to 1.12, representing a 2.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Vivesto since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Vivesto with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Vivesto

All Key Metrics — Vivesto